NOTICE TO THE MARKET

Grupo Biotoscana announces extension of agreement with Biocad to include exclusive license for Infliximab in Colombia

Montevideo, Uruguay, March 2, 2018. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that it has made an amendment to the agreement with JSC Biocad, a Russian innovative biotechnology company, to exclusively register, market and commercialize Infliximab in Colombia.

Under Under the existing agreement, GBT is responsible for the marketing authorizations, market access, commercialization and distribution of Rituximab, Bevacizumab, Trastuzumab and Adalimumab in four countries and now for Infliximab in Colombia.

GBT – Grupo Biotoscana.
ir@grupobiotoscana.com

To access the PDF version, please click here.

Updated on 01/02/2019 at 04:39 pm